• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Moderna (MRNA) Faces A Fresh Valuation Test Following Its Flu Vaccine Decision

    Simply Wall St·07/12/2026 16:19:17
    Listen to the news

    Board appointment and flu vaccine decision put Moderna in focus

    Interest in Moderna (MRNA) is being driven by an upcoming regulatory decision on its mRNA-1010 seasonal flu vaccine, alongside boardroom changes that refresh financial oversight and governance at the company.

    Against that backdrop, Moderna stock has been volatile, including an 11% pullback after a recent rally, as investors weigh the potential impact of an expanded pipeline in oncology and respiratory vaccines.

    See our latest analysis for Moderna.

    Against the current backdrop, Moderna’s share price has pulled back sharply in the last week. It still shows a strong 30 day share price return of 36.79% and a year to date share price return of 121.22%, while the 1 year total shareholder return of 102.94% contrasts with weaker 3 and 5 year total shareholder returns.

    If this kind of volatility has your attention, it could be a good moment to look across the sector and see how other healthcare related AI opportunities compare through the 41 healthcare AI stocks

    After Moderna’s sharp year to date rebound, continued losses, and a price now sitting well above the average analyst target, investors are effectively choosing between upside still ahead or most of it already behind the stock as valuation comes into focus.

    Most Popular Narrative: 54.3% Overvalued

    Compared with Moderna’s last close at $68.27, the most followed narrative framework points to a fair value of $44.25. This puts valuation firmly under the microscope for anyone watching the stock’s recent swings.

    The analysts have a consensus price target of $44.25 for Moderna based on their expectations of its future earnings growth, profit margins and other risk factors.

    However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $77.0, and the most bearish reporting a price target of just $22.0.

    Read the complete narrative.

    Want to understand why this framework sits well below the current share price? The answer rests on a specific mix of high revenue growth, rising margins, and a demanding future earnings multiple that all need to line up. The tension between those assumptions and today’s valuation is what drives the $44.25 figure.

    Result: Fair Value of $44.25 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Moderna’s story could change quickly if COVID and RSV sales weaken further, or if regulators tighten on pricing and approvals for its newer vaccines.

    Find out about the key risks to this Moderna narrative.

    Next Steps

    Given the mixed sentiment around Moderna, it makes sense to move quickly, review the data for yourself, and decide where you stand. To see what is driving current optimism, take a closer look at the 1 key reward

    Looking for more investment ideas beyond Moderna?

    If Moderna has sharpened your focus on opportunities and risks, now is a smart time to scan wider, compare different setups, and see what else could fit your portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.